Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1993 Sep;93(3):350–355. doi: 10.1111/j.1365-2249.1993.tb08184.x

Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes.

A Kalinkovich 1, G Livshits 1, H Engelmann 1, N Harpaz 1, R Burstein 1, M Kaminsky 1, D Wallach 1, Z Bentwich 1
PMCID: PMC1554913  PMID: 8396513

Abstract

The objective of this study was to determine sTNF-R, type I (p55) and type II (p75) in sera of HIV-infected male homosexuals and correlate them to T lymphocyte subpopulations and course of HIV infection. Serum samples were obtained from 39 HIV-1+ asymptomatic male homosexuals, 10 symptomatic (ARC and AIDS) male homosexuals and 44 HIV- non-homosexual healthy controls. sTNF-R levels were determined by ELISA with specific MoAbs and polyclonal antibodies to the sTNF-R proteins. sTNF-RI and II levels were significantly elevated in 72% and 74% respectively of HIV+ asymptomatic male homosexuals and in all of the symptomatic male homosexuals. In sequential studies a highly significant positive correlation was found between sTNF-RI and sTNF-RII (r = 0.8, P < 0.001) and between both sTNF-R and CD8+ lymphocyte counts (r = 0.6 and 0.92, respectively, P < 0.01-0.001) during the asymptomatic stage of the infection. All these correlations were lost, however, during the symptomatic phase of the disease. These results suggest that: (i) HIV infection is associated with elevation of sTNF-R serum levels; (ii) sTNF-R levels are strongly correlated to CD8+ lymphocytes during the asymptomatic stage of HIV infection.

Full text

PDF
350

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Englemann H., Hornik V., Skornick Y., Levo Y., Wallach D., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed] [Google Scholar]
  2. Agostini C., Pizzolo G., Zambello R., Trentin L., Siviero F., Vinante F., Morosato L., Francavilla E., Cadrobbi P., Semenzato G. Shedding of the soluble form of the CD8 complex by CD8+/HLA-DR+ cells in HIV-1-infected patients. AIDS. 1991 Jul;5(7):813–819. doi: 10.1097/00002030-199107000-00004. [DOI] [PubMed] [Google Scholar]
  3. Agostini C., Semenzato G., Vinante F., Sinicco A., Trentin L., Zambello R., Zuppini B., Zanotti R., Siviero F., Veneri D. Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. Clin Immunol Immunopathol. 1989 Jan;50(1 Pt 1):146–153. doi: 10.1016/0090-1229(89)90229-8. [DOI] [PubMed] [Google Scholar]
  4. Arditi M., Kabat W., Yogev R. Serum tumor necrosis factor alpha, interleukin 1-beta, p24 antigen concentrations and CD4+ cells at various stages of human immunodeficiency virus 1 infection in children. Pediatr Infect Dis J. 1991 Jun;10(6):450–455. doi: 10.1097/00006454-199106000-00007. [DOI] [PubMed] [Google Scholar]
  5. Bass H. Z., Nishanian P., Hardy W. D., Mitsuyasu R. T., Esmail E., Cumberland W., Fahey J. L. Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens. Clin Immunol Immunopathol. 1992 Jul;64(1):63–70. doi: 10.1016/0090-1229(92)90060-2. [DOI] [PubMed] [Google Scholar]
  6. Breen E. C., Rezai A. R., Nakajima K., Beall G. N., Mitsuyasu R. T., Hirano T., Kishimoto T., Martinez-Maza O. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol. 1990 Jan 15;144(2):480–484. [PubMed] [Google Scholar]
  7. Chikanza I. C., Roux-Lombard P., Dayer J. M., Panayi G. S. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol. 1993 Apr;92(1):19–22. doi: 10.1111/j.1365-2249.1993.tb05941.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cope A. P., Aderka D., Doherty M., Engelmann H., Gibbons D., Jones A. C., Brennan F. M., Maini R. N., Wallach D., Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992 Oct;35(10):1160–1169. doi: 10.1002/art.1780351008. [DOI] [PubMed] [Google Scholar]
  9. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989 Jul 15;264(20):11974–11980. [PubMed] [Google Scholar]
  10. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990 Jan 25;265(3):1531–1536. [PubMed] [Google Scholar]
  11. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991 Aug;5(11):2567–2574. doi: 10.1096/fasebj.5.11.1868981. [DOI] [PubMed] [Google Scholar]
  12. Fuchs D., Hausen A., Reibnegger G., Werner E. R., Dierich M. P., Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today. 1988 May;9(5):150–155. doi: 10.1016/0167-5699(88)91203-0. [DOI] [PubMed] [Google Scholar]
  13. Gatanaga T., Hwang C. D., Kohr W., Cappuccini F., Lucci J. A., 3rd, Jeffes E. W., Lentz R., Tomich J., Yamamoto R. S., Granger G. A. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8781–8784. doi: 10.1073/pnas.87.22.8781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Godfried M. H., van der Poll T., Jansen J., Romijin J. A., Schattenkerk J. K., Endert E., van Deventer S. J., Sauerwein H. P. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS. 1993 Jan;7(1):33–36. [PubMed] [Google Scholar]
  15. Grimaldi L. M., Martino G. V., Franciotta D. M., Brustia R., Castagna A., Pristerà R., Lazzarin A. Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Ann Neurol. 1991 Jan;29(1):21–25. doi: 10.1002/ana.410290106. [DOI] [PubMed] [Google Scholar]
  16. Hartmann W., Hitzler H., Schlickenrieder J. H., Zapf J., Heit W., Gaedicke G., Vetter U. Heterogeneity of insulin and insulin-like growth factor I binding in a human Burkitt type ALL cell line during the cell cycle and in three Burkitt type ALL sublines. Leukemia. 1988 Apr;2(4):241–244. [PubMed] [Google Scholar]
  17. Jones P. D., Shelley L., Wakefield D. Tumor necrosis factor-alpha in advanced HIV infection in the absence of AIDS-related secondary infections. J Acquir Immune Defic Syndr. 1992 Dec;5(12):1266–1271. [PubMed] [Google Scholar]
  18. Kalinkovich A., Engelmann H., Harpaz N., Burstein R., Barak V., Kalickman I., Wallach D., Bentwich Z. Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol. 1992 Sep;89(3):351–355. doi: 10.1111/j.1365-2249.1992.tb06961.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kobayashi S., Hamamoto Y., Kobayashi N., Yamamoto N. Serum level of TNF alpha in HIV-infected individuals. AIDS. 1990 Feb;4(2):169–170. [PubMed] [Google Scholar]
  20. Lantz M., Malik S., Slevin M. L., Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 1990 Nov;2(6):402–406. doi: 10.1016/1043-4666(90)90048-x. [DOI] [PubMed] [Google Scholar]
  21. Lesslauer W., Tabuchi H., Gentz R., Brockhaus M., Schlaeger E. J., Grau G., Piguet P. F., Pointaire P., Vassalli P., Loetscher H. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol. 1991 Nov;21(11):2883–2886. doi: 10.1002/eji.1830211134. [DOI] [PubMed] [Google Scholar]
  22. Levacher M., Hulstaert F., Tallet S., Ullery S., Pocidalo J. J., Bach B. A. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol. 1992 Dec;90(3):376–382. doi: 10.1111/j.1365-2249.1992.tb05854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Loetscher H., Steinmetz M., Lesslauer W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells. 1991 Jun;3(6):221–226. [PubMed] [Google Scholar]
  24. Lähdevirta J., Maury C. P., Teppo A. M., Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Sep;85(3):289–291. doi: 10.1016/0002-9343(88)90576-1. [DOI] [PubMed] [Google Scholar]
  25. Matsuyama T., Kobayashi N., Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS. 1991 Dec;5(12):1405–1417. doi: 10.1097/00002030-199112000-00001. [DOI] [PubMed] [Google Scholar]
  26. Miles D. W., Aderka D., Engelmann H., Wallach D., Balkwill F. R. Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. Br J Cancer. 1992 Dec;66(6):1195–1199. doi: 10.1038/bjc.1992.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mintz M., Rapaport R., Oleske J. M., Connor E. M., Koenigsberger M. R., Denny T., Epstein L. G. Elevated serum levels of tumor necrosis factor are associated with progressive encephalopathy in children with acquired immunodeficiency syndrome. Am J Dis Child. 1989 Jul;143(7):771–774. doi: 10.1001/archpedi.1989.02150190021012. [DOI] [PubMed] [Google Scholar]
  28. Nishanian P., Hofmann B., Wang Y., Jackson A. L., Detels R., Fahey J. L. Serum soluble CD8 molecule is a marker of CD8 T-cell activation in HIV-1 disease. AIDS. 1991 Jul;5(7):805–812. doi: 10.1097/00002030-199107000-00003. [DOI] [PubMed] [Google Scholar]
  29. Noronha I. L., Daniel V., Schimpf K., Opelz G. Soluble IL-2 receptor and tumour necrosis factor-alpha in plasma of haemophilia patients infected with HIV. Clin Exp Immunol. 1992 Feb;87(2):287–292. doi: 10.1111/j.1365-2249.1992.tb02989.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Olsson I., Gullberg U., Lantz M., Peetre C. A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF. Biotherapy. 1991;3(2):159–165. doi: 10.1007/BF02172088. [DOI] [PubMed] [Google Scholar]
  31. Olsson I., Lantz M., Nilsson E., Peetre C., Thysell H., Grubb A., Adolf G. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 1989 Mar;42(3):270–275. doi: 10.1111/j.1600-0609.1989.tb00111.x. [DOI] [PubMed] [Google Scholar]
  32. Osmond D. H., Shiboski S., Bacchetti P., Winger E. E., Moss A. R. Immune activation markers and AIDS prognosis. AIDS. 1991 May;5(5):505–511. doi: 10.1097/00002030-199105000-00005. [DOI] [PubMed] [Google Scholar]
  33. Porteu F., Brockhaus M., Wallach D., Engelmann H., Nathan C. F. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem. 1991 Oct 5;266(28):18846–18853. [PubMed] [Google Scholar]
  34. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990 Aug 1;172(2):599–607. doi: 10.1084/jem.172.2.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Prince H. E., Kleinman S., Czaplicki C., John J., Williams A. E. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr. 1990;3(5):525–530. [PubMed] [Google Scholar]
  36. Rautonen J., Rautonen N., Martin N. L., Philip R., Wara D. W. Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS. 1991 Nov;5(11):1319–1325. doi: 10.1097/00002030-199111000-00006. [DOI] [PubMed] [Google Scholar]
  37. Reddy M. M., Lange M., Grieco M. H. Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations. J Clin Microbiol. 1989 Feb;27(2):257–260. doi: 10.1128/jcm.27.2.257-260.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Redfield R. R., Wright D. C., Tramont E. C. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med. 1986 Jan 9;314(2):131–132. doi: 10.1056/NEJM198601093140232. [DOI] [PubMed] [Google Scholar]
  39. Roux-Lombard P., Modoux C., Cruchaud A., Dayer J. M. Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol. 1989 Mar;50(3):374–384. doi: 10.1016/0090-1229(89)90144-x. [DOI] [PubMed] [Google Scholar]
  40. Schattner A., Hanuka N., Sarov B., Sarov I., Handzel Z., Bentwich Z. Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion. Clin Exp Immunol. 1991 Aug;85(2):209–213. doi: 10.1111/j.1365-2249.1991.tb05706.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Seckinger P., Isaaz S., Dayer J. M. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem. 1989 Jul 15;264(20):11966–11973. [PubMed] [Google Scholar]
  42. Sethi K. K., Näher H. Elevated titers of cell-free interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome. Immunol Lett. 1986 Oct;13(4):179–184. doi: 10.1016/0165-2478(86)90052-0. [DOI] [PubMed] [Google Scholar]
  43. Tomkinson B. E., Brown M. C., Ip S. H., Carrabis S., Sullivan J. L. Soluble CD8 during T cell activation. J Immunol. 1989 Apr 1;142(7):2230–2236. [PubMed] [Google Scholar]
  44. Van Zee K. J., Kohno T., Fischer E., Rock C. S., Moldawer L. L., Lowry S. F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845–4849. doi: 10.1073/pnas.89.11.4845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Vanham G., Kestens L., Penne G., Goilav C., Gigase P., Colebunders R., Vandenbruaene M., Goeman J., van der Groen G., Ceuppens J. L. Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. J Clin Immunol. 1991 Nov;11(6):345–356. doi: 10.1007/BF00918800. [DOI] [PubMed] [Google Scholar]
  46. Watret K. C., Whitelaw J. A., Froebel K. S., Bird A. G. Phenotypic characterization of CD8+ T cell populations in HIV disease and in anti-HIV immunity. Clin Exp Immunol. 1993 Apr;92(1):93–99. doi: 10.1111/j.1365-2249.1993.tb05953.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Zolla-Pazner S., William D., El-Sadr W., Marmor M., Stahl R. Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome. JAMA. 1984 Jun 8;251(22):2951–2955. [PubMed] [Google Scholar]
  48. von Sydow M., Sönnerborg A., Gaines H., Strannegård O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses. 1991 Apr;7(4):375–380. doi: 10.1089/aid.1991.7.375. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES